Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaFrancesco Lo‐Coco, Uwe Platzbecker, Lorella Melillo et al.|New England Journal of Medicine|2013Cited by 1.6k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
Diagnostic capabilities, clinical features, and longitudinal <scp><i>UBA1</i></scp> clonal dynamics of a nationwide <scp>VEXAS</scp> cohortCarmelo Gurnari, Maria Teresa Voso, Maria Rosaria Pascale et al.|American Journal of Hematology|2023Cited by 43
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Filíppo Gherlinzoni, Francesca Palandri et al.|Cancer|2025Cited by 10
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Elena Maria Elli et al.|Cancer|2024Cited by 10